|
Scientific Publications:
Rocha Lima CMS, Herndon JE II, Kosty M, Clamon G,
Green MR. Therapy choices among older patients with
lung carcinoma: An evaluation of two trials of the
Cancer and Leukemia Group B. Cancer 94: 181-7, 2002
Rocha Lima CMS, Savarese D, Bruckner H, Dudek A,
Eckhardt J, Hainsworth J, Yunas F, Lester E, Miller
W, Saville W, Elfring G, Locker P, Compton L, Miller
LL, Green MR. Irinotecan plus gemcitabine induces
both radiographic and CA 19-9 tumor marker responses
in patients with previously untreated advanced pancreatic
cancer. J Clin Oncol 20:1182-91, 2002
Green MR. The evolving role of Gemcitabine and Pemetrexed
[AlimtaR] in the management of patients with mesothelioma.
Clinical Lung Cancer 3 [suppl 1]: s26-s29, 2002
Blackstock AW, Herndon JE 2nd, Paskett ED, Perry
MC, Graziano SL, Muscato JJ, Kosty MP, Akerley WI,
Holland J, Fleishman S, Green MR. Outcomes among African-American/non
African-American patients with advanced non-small
cell lung carcinoma: report from Cancer and Leukemia
Group B studies 8931, 8932, 9132, 9532, and 9731.
JNCI 94: 284 - 290, 2002
Rocha Lima CMS, Urbanic JJ, Sherman CA, Brescia
FJ, Green MR: Docetaxel followed by gemcitabine and
irinotecan in solid tumors. Oncology 15:1(suppl 1):
37-45, 2001
Kindler HL, Millard F, Herndon JE, Vogelzang NJ,
Suzuki Y, Green MR: Gemcitabine for malignant mesothelioma:
A phase II trial by the Cancer and Leukemia Group
B. Lung Cancer 31: 311-319, 2001
Niell HB, Perry MC, Clamon G, Crawford J, Miller
AA, Herndon J II, Green MR. Carboplatin etoposide
and paclitaxel in the treatment of patients with extensive
small cell lung cancer. Clinical Lung Cancer 2:204
-09, 2001
Green, MR. The current status of docetaxel for advanced
non-small cell lung cancer. Anti- Cancer Drugs 12:
S11 - S17, 2001
Breathnach OS, Freidlin B, Conley B, Green MR, Johnson
DH, Gandara DR, O'Connell M, Shepherd FA, Johnson
BE. Twenty-two years of phase III trials for patients
with advanced non-small cell lung cancer: Sobering
results. J Clin Oncol 19:1734 - 42, 2001
Loeher PJ, Jiroutek M, Aisner S, Aisner J, Green
M, Thomas CR, Livingston R, Johnson DH. Combined etoposide,
ifosfamide, and cisplatin in the treatment of patients
with advanced thymoma and thymic carcinoma: An intergroup
trial. Cancer 91: 2010-15, 2001
Graziano SL, Tatum A, Herndon JE, Box J, Memoli V,
Green MR, Kern JA. Use of neuroendocrine markers,
p53, and HER2 to predict response to chemotherapy
in patients with stage III non-small cell lung cancer:
A Cancer and Leukemia Group B study. Lung Cancer 33:
115-24, 2001
Bahadori HR, Green MR, Catapano CV. Synergistic interaction
between topotecan and microtubule-interfering agents.
Cancer Chemother Pharmacol 48:188 - 96, 2001
Kosty MP, Herndon JE 2nd, Vogelzang NJ, Kindler HL,
Green MR. High-dose doxorubicin, dexrazoxane, and
GM-CSF in malignant mesothelioma: a phase II study-Cancer
and Leukemia Group B 9631. Lung Cancer 34:289-95,
2001
Perry MC, Ihde DC, Herndon JE 2nd, Grossbard ML,
Grethein SJ, Atkins JN, Vokes EE, Green MR: Paclitaxel/ifosfamide
or navelbine/ifosfamide chemotherapy for advanced
non-small cell lung cancer: CALGB 9532. Lung Cancer
28(1):63-8, 2000
Cappuzzo F, Rocha Lima CM, Sherman CA, Green MR:
Advances in treatment of inoperable NSCLC: gemcitabine
doublets--a promising alternative. Oncology (Huntingt)
14(7 Suppl 4):7-14, 2000
Green MR, Rocha-lima CM, Sherman CA: Radiation and
chemotherapy for patients with stage III non-small
cell lung cancer. Semin Rad Oncol 10: 289 - 296, 2000
Shepherd FA, Abratt R, Crino L, Green M, Sandler
A, Steward W, Iglesias J, Anglin G: The influence
of gemcitabine and cisplatin schedule on response
and survival in advanced non-small cell lung cancer.
Lung Cancer 30: 117 - 125, 2000
Green MR, Harper M, Safa A, Sherman CA, Mushtaq CM,
Bahadori H Brescia FJ, Rocha Lima CMSP: Irinotecan
in the Management of Patients with Pancreatic Cancer.
Oncology 14:12(suppl 14): 31-33, 2000
Clamon G, Herndon J, Cooper R, Chang AY, Rosenman
J, Green MR: Radiosensitization with carboplatin for
patients with unresectable stage III non-small cell
lung cancer: a phase III trial of the Cancer and Leukemia
Group B and the Eastern Cooperative Oncology Group.
J Clin Oncol 17(1):4-11, 1999
Tran YK, Bogler O, Gorse KM, Wieland I, Green MR,
Newsham IF: A novel member of the NF2/ERM/4.1 superfamily
with growth suppressing properties in lung cancer.
Cancer Research 59:35-43, 1999
Herndon JE, Fleishman S, Kornblith Alice, Kosty M,
Green MR, Holland J: Is quality of life predictive
of the survival of patients with advanced nonsmall
cell lung carcinoma? Cancer 85(2):333-340, 1999
Vogelzang NJ, Herndon II JE, Miller A, Strauss G,
Clamon G, Stewart FM, Aisner J, Lyss A, Cooper MR,
Suzuki Y, Green MR: High-dose paclitaxel plus G-CSF
for malignant mesothelioma: CALGB phase II study 9234.
Annals of Oncology 10:597-600, 1999
Krasna MJ, Reed CE, Nugent WC, Olak J, Sugarbaker
DJ, Green MR, Kohman LJ: Lung Cancer Staging and Treatment
in Multidisciplinary Trials: Cancer and Leukemia Group
B Cooperative Group Approach. Ann Thorac Surg 68:201-207,
1999
Rocha Lima CM, Leong SS, Sherman CA, Perkel JA, Putman-Hair
T, Safa AR, Green MR: Phase I Study of CPT-11 and
Gemcitabine in Patients with Solid Tumors. Cancer
Therapeutics 2:58-66, 1999
Rocha Lima CM, Eckardt JR, Leong SS, Sherman CA,
Perkel JA, Putnam T, Safa AR, Bahadori HR, Green MR:
Single-Agent Gemcitabine and Gemcitabine/Irinotecan
Combination (IrinoGem) in Non-Small Cell Lung Cancer.
Seminars in Onc 26(5) Supp 16:43-50, 1999
Leong SS, Rocha Lima CM, Sherman CA, Green MR: The
1997 international staging system for non-small cell
lung cancer: have all the issues been addressed? CHEST
115: 242-248, 1999
Postmus Pieter E, Green Mark R: Overview of mta in
the treatment of non-small cell lung cancer. Seminars
in Oncology 26(1) Suppl 4: 1999
Kindler HL, Belani CP, Herndon JE, Vogelzang NJ,
Suzuki Y, Green MR: Edatrexate (10-Ethyl-Deasa-Aminopterin)
(NSC #626715) with or without Leucovorin Rescue for
Malignant Mesothelioma. Cancer 86(10):1985-1991, 1999
Vokes EE, Green MR: Current strategies for locoregionally
advanced unresectable non-small cell lung cancer.
Seminars in Oncology 26(5) Suppl 15:40-43, 1999
Bahadori HR, Rocha Lima CM, Green MR, Safa AR: Synergistic
Effect of Gemcitabine and Irinotecan (CPT-11) on Breast
and Small Cell Lung Cancer Cell Lines. Anticancer
Research 19:1-6, 1999
Clamon G, Herndon J, Akerley W, Green M: Subcutaneous
interleukin-2 initial therapy for patients with extensive
small cell lung cancer: a phase II trial of Cancer
and Leukemia Group B. Lung Cancer 19(1):25-29, 1998
Vokes EE, Green MR: Clinical studies in non-small
cell lung cancer: the CALGB experience. Cancer Invest
16(2):72-79, 1998
Ogretmen B, Bahadori HR, McCauley MD, Boylan A, Green
MR, Safa AR: Co-ordinated over-expression of the MRP
and ?-glutamylcysteine synthetase genes, but not MDR1,
correlates with doxorubicin resistance in human malignant
mesothelioma cell lines. Int J Cancer 75:757-761,
1998
Rafi I, Boddy AV, Calvete JA, Taylor GA, Newell DR,
Bailey NP, Lind MJ, Green M, Hines J, Johnstone A,
Clendeninn N, Calvert AH: Preclinical and phase I
clinical studies with the nonclassical antifolate
thymidylate synthase inhibitor nolatrexed dihydrochloride
given by prolonged administration in patients with
solid tumors. J Clin Oncol 16(3):1131-1141, 1998.
Ahles TA, Silberfarb PM, Herndon II J, Maurer LH,
Kornblith AB, Aisner J, Perry MC, Eaton WL, Zacharski
LL, Green MR, Holland JC: Psychologic and Neuropsychologic
functioning of patients with limited small-cell lung
cancer treated with chemotherapy and radiation therapy
with or without warfarin. J Clin Oncol 16:1954-1960,
1998
Perry MC, Herndon III JE, Eaton WL, Green MR: Thoracic
radiation therapy added to chemotherapy for small-cell
lung cancer.An update of CALGB 8083. J Clin Oncol
16:2466-2467, 1998
Lilenbaum RC, MacManus D, Engstrom C, Green M: Phase
I study of paclitaxel and etoposide for metastatic
or recurrent malignancies. Am J Clin Oncol (CCT) 21(2):129-134,
1998
Budman DR, Berry DA, Cirrincione CT, Henderson IC,
Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton
L, Frei E.III: Dose and Dose Intensity as Determinants
of Outcome in the Adjuvant Treatment of Breast Cancer.
Journal of the National Cancer Institute 90(16):1205-1211,
1998
Graziano SL, Kern JA, Herndon JE, Tatum A, Brisson
ML, Memoli V, Sugarbaker D, Skarin AT, Kreisman H,
Green MR: Analysis of neuroendocrine markers, HER2
and CEA before and after chemotherapy in patients
with stage IIIA non-small cell lung cancer: A Cancer
and Leukemia Group B study. Lung Cancer 21:203-211,
1998
Tran Y, Benbatoul K, Gorse K, Rempel S, Futreal A,
Green M, Newsham I: Novel regions of allelic deletion
on chromosome 18p in tumors of the lung, brain and
breast. Oncogene 17:2499-3505, 1998
Miller AA, Rosner GL, Ratain MJ, Hollis DR, Green
MR, Schilsky RL: Pharmacology of 21-day oral etoposide
given in combination with i.v. cisplatin in patients
with extensive-stage small cell lung cancer: a Cancer
and Leukemia Group B study (CALGB 9062). Clin Cancer
Res 3:719-725, 1997
Vogelzang NJ, Herndon JE, Cirrincione C, Harmon DC,
Antman KH, Corson JM, Suzuki Y, Citron ML, Green MR,
for the Cancer and Leukemia Group B: Dihydro-5-azacytidine
in malignant mesothelioma: a phase II trial demonstrating
activity accompanied by cardiac toxicity. Cancer 79(11):2237-2242,
1997
Vokes EE, Leopold KA, Herndon J, Green MR: Investigations
of new drugs in combination with cisplatin in stage
III non-small cell lung cancer. Sem in Oncol 24(3)
Suppl 8:42-45, 1997
Green MR, Barkley JE: Intensity of neoadjuvant therapy
in resectable non-small cell lung cancer. Lung Cancer
17 Suppl 1:S111-S119, 1997
Luikart SD, Herndon JE II, Hollis DR, MacDonald M,
Maurer LH, Crawford J, Clamon GH, Wright J, Perry
MC, Ozer H, Green MR: Phase I trial of etoposide,
carboplatin, and GM-CSF in extensive small-cell lung
cancer a Cancer and Leukemia Group B study (CALGB
8832). J Clin Oncol 20(1):24-30, 1997
Maurer LH, Herndon JE II, Hollis DR, Aisner J, Carey
RW, Skarin AT, Perry MC, Eaton WL, Zacharski LL, Hammond
S, Green MR: Randomized trial of chemotherapy and
radiation therapy with or without warfarin for limited-stage
small-cell lung cancer: a Cancer and Leukemia Group
B study. J Clin Oncol 15(11):3378-3387, 1997
Niell HB, Miller AA, Clamon GH, Perry MC, Crawford
J, Green MR: A phase II study evaluating the efficacy
of carboplatin, etoposide, and paclitaxel with granulocyte
colony-stimulating pactor in patients with stage IIIB
and IV non-small cell lung cancer and extensive small
cell lung cancer. Sem in Oncol 24(4 suppl 12):130-134,
1997
Rothenberg ML, Moore MJ, Cripps MC, Andersen JS,
Portenoy RK, Burris HA, Green MR, Tarassoff PG, Brown
TD, Casper ES, Storniolo AM, Von Hoff DD: A phase
II trial of gemcitabine in patients with 5-FU refractory
pancreas cancer. Annl of Oncol 7:347-353, 1996
Mitchell EP, Perry MC, Luikart SD, Cirrincione CT,
Van Echo DA, Herndon JE II, Maurer LH, Clamon G, Green
MR: A phase I/II trial of etoposide and cisplatin
in extensive small cell lung cancer: a Cancer and
Leukemia Group B study. Lung Cancer 15(2):215-223,
1996
Graziano SL, Valone FH, Herndon JE II, Crawford J,
Richards F II, Rege VB, Clamon G, Green MR: A randomized
phase II study of ifosfamide/mesna/cisplatin plus
G-CSF or etoposide/cisplatin plus G/CSF in advanced
non-small cell lung cancer: a Cancer and Leukemia
Group B study. Lung Cancer 14:315-329, 1996
Green MR: Gemcitabine safety overview. Seminars in
Oncology, Yarbo JW, Bornstein RS, Mastrangelo MJ (eds),
23(4) suppl 10:32-35. WB Saunders, Philadelphia, PA,
1996.
Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green
MR: Improved survival in stage III non-small-cell
lung cancer: seven-year follow-up of Cancer and Leukemia
Group B (CALGB) 8433 trial. JNCI 88(17):1210-1215,
1996
Barkley J, Green MR: Brochioloalveolar carcinoma.
J Clin Oncol 14(8):2377-2386, 1996
Barkley J, Green MR: Managing stage III non-small
cell lung cancer. J Resp Dis 17(10):858-868, 1996
Bitran JD, Green MR, Perry M, Hollis DR, Herndon
JE II: A phase II study of recombinant interferon-gamma
following combination chemotherapy for patients with
extensive small cell lung cancer. Am J Clin Oncol
18(1):67-70, 1995
Sorscher SM, Green MR, Feramisco JR: Enhanced E-cadherin
expression in epidermal growth factor receptor expressing
cells. Biochem and Biophy Res Comm 206(2):518-524,
1995
Sorscher SM, Russack V, Cagle M, Feramisco JR, Green
MR: Immunolocalization of E-cadherin in human head
and neck cancer. Arch Path Lab Med 119:82-84, 1995
Green MR: Multimodality therapy in unresected stage
III non-small cell lung cancer: the American Cooperative
Groups' experience. Lung Cancer, IASLC 12(suppl 1):S87-S94,
1995
Sorscher SM, Russack V, Graziano S, Cagle M, Feramisco
JE, Green MR: Immunohistochemical evaluation of E-cadherin
and epidermal growth factor receptor in non-small
cell lung cancer. Modern Pathol 8(2):450-455, 1995
Miller AA, Herndon JE II, Hollis DR, Ellerton J,
Langleben A, Richards F II, Green MR: Schedule dependency
of 21-day oral versus 3-day intravenous etoposide
in combination with intravenous cisplatin in extensive-stage
small-cell lung cancer: a randomized phase III study
of Cancer and Leukemia Group B. J Clin Onc 13(8):1871-1879,
1995
Green MR, Lilenbaum RC: Issues at the cutting edge
in stage III non-small-cell lung cancer. Annl of Oncol
6(supple 3):S33-S36, 1995
Alberti W, Anderson G, Bartolucci A, Bell D, Villalba
JC, Brodin O, Cardiello C, Cartei F, Cartei G, Cellerino
R, Chastang C, Comier Y, Cox JD, Crino L, Crowley
J, Dautzenberg B, Depierre A, Dietermann A, Dillman
RO, Doi O, Feld R, Figlin R, Ganz PA, Green MR: Chemotherapy
in non-small cell lung cancer: a meta-analysis using
updated data on individual patients from 52 randomized
clinical trials. BMJ 311:899-909, 1995
Sugarbaker DJ, Herndon J, Kohman LJ, Krasna MJ, Green
MR, Cancer and Leukemia Group B Thor Surg Group: Results
of Cancer and Leukemia Group B Protocol 8935: a multi
institutional phase II study trimodality trial for
stage IIIA (N2) non-small cell lung cancer. J Thorac
Cardiovasc Surg 109:473-485, 1995
Muscato JJ, Cirrincione C, Clamon G, Perry MC, Omura
G, Berkowitz I, Reid T, Herndon JE II, Green MR: Etoposide
(VP-16) and cisplatin at maximum tolerated dose in
non-small cell lung carcinoma: a Cancer and Leukemia
Group B study. Lung Cancer, IASLC 13:285-294, 1995
Aisner J, Albain K, Belani CP, Bunn PA, Choy H, Glantz
M, Greco FA, Green MA, Ozols RF, Perez EA: TAXOL (Paclitaxel)
for injection concentrate: clinical experience in
an outpatient setting. Princeton, Bristol-Myers Squibb
Company, 1994
Kosty MP, Fleishman SB, Herndon JE II, Coughlin K,
Kornblith AB, Scalzo A, Morris JC, Mortimer J, Green
MR: Cisplatin, vinblastine, and hydrazine sulfate
in advanced, non-small cell lung cancer: a randomized
placebo-controlled, double-blind phase III study of
the Cancer and Leukemia Group B. J Clin Onc 12(6):1113-20,
June 1994
Green MR, Lilenbaum, RC: Stage IIIA Category of non-small
cell lung cancer; a new proposal. JNCI, 86(8):586-8,
1994
Green MR, Multimodal therapy for solid tumors. NEJM,
330(3):206-7, 1994
Casper ES, Green, MR, Kelsen, DP, Heelan RT, Brown
TD, Flombaum CD, Trochanowswki B, Tarasoff PG: Phase
II trial of gemciatabine (2,2'-difluorodeoxycytidine)
in patients with adenocarcinoma of the pancreas. Invest
New Drugs 12:29-34, 1994
Clamon G, Herndon J, Eaton W, Rosenman J, Maurer
LH, Cooper MR, Green MR: A feasibility study of extended
chemotherapy for locally advanced non-small cell lung
cancer: a phase II trial of Cancer and Leukemia Group
B. Cancer Invest 12(3):273-282, 1994
Green MR, Kosty MP, Muscato J, Graziano S, Dillman
RO, Clamon GH, Herndon J: Nonoperative management
of non-small cell lung cancer: the current Cancer
and Leukemia Group B experience. Semin Onc 21(suppl
6):60-65, 1994
Sorscher SM, Pellitteri P, Robbins KT, Cagle M, Feramisco
JR, Green MR, Russack V: Immunolocalization of the
retinoblastoma and Myc proteins in human head and
neck cancer. Appl Immunohistochem 2(2):81-88, 1994
George SL, Li C, Berry DA, Green MR: Stopping a clinical
trial early: frequentist and bayesian approaches applied
to a cancer trial in non-small-cell lung cancer. Stat
in Med 13:1313-1327, 1994
Lilenbaum RC, Green MR: Multimodality therapy for
non-small cell lung cancer. Oncology 8:25-31, 1994
Vogelzang NJ, Weissman LB, Herndon JE II, Antman
KH, Cooper MR, Corson JM, Green MR: Trimetrexate in
malignant mesothelioma: a Cancer and Leukemia Group
B phase II study. J Clin Oncol 12:1436-1442, 1994
Ahles TA, Silberfarb PM, Rundle AC, Holland JC, Kornblith
AB, Canellos GP, Green MR, Perry MC: Quality of life
in pateints with limited small cell carcinoma of the
lung receiving chemotherapy with or without radiation
therapy, for Cance and Leukemia Group B. Psychother
Psychosom 62:193-199, 1994
Green MR, Ginsberg R, Ardizzoni A, Choi N, Darwish
S, Fukuoka M, Giner V, Grunenwald D, Harper P, Kho
S, Le Chevalier T, Lewinski T, Payne D, Postmus P,
Rochmans P, Rosell R, Roth J, Sculier JP, Sorensen
JB: Induction therapy for stage III NSCLC: a consensus
report. Lung Cancer 11(suppl 3):S9-S10, 1994
Green MR: The role of induction chemotherapy before
radiation therapy in non-operative management of stage
III NSCLC. Lung Cancer 11(suppl 3):S55-S65, 1994
Green MR, Cox JD, Ardizzoni A, Arriagada R, Bureau
G, Darwish S, Deneffe G, Fukuoka M, Joseph D, Komaki
R, Mirimanoff RO, Mornex F, Palazzi M, Pastorino U,
Pavy JJ, Postmus PE, Roth J, Rubin P, Saijo N, Saunders
M, Stout R, Sutedja TG, Trovo MG: Endpoints for multimodal
clinical trials in stage III non-small cell lung cancer
(NSCLC): a consensus report. Lung Cancer 11(suppl
3):S11-S13, 1994
Seagren SL, Herndon JE, Baeker JR, Boles M, Chung
C, Green MR: Alternating irradiation and chemotherapy
in stage IIIA and B non-small cell lung cancer: Report
of a Cancer and Leukemia Group B phase II study 8636.
Int J Radiation Oncology Biol Phys 29:1085-1088, 1994
Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green
MR: Multicenter phase II efficacy trial of toremifene
in tamoxifen-refractory patients with advanced breast
cancer. J Clin Oncol 11:345-350, 1993
Parker BA, Santarelli M, Green MR, Anderson JR, Cooper
MR, Case D Jr., Barcos M, Peterson BA, Gottlieb AJ:
AMOPLACE Treatment of Intermediate-Grade and High-Grade
Malignant Lymphoma: A Cancer and Leukemia Group B
Study. J Clin Oncol 11:248-254, 1993
Clamon G, Herndon J, Perry MC, Ozer H, Kreisman H,
Maher T, Ellerton J, Green MR: Interleukin-2 activity
in patients with extensive small-cell lung cancer:
A phase II trial of Cancer and Leukemia Group B. J
Natl Cancer Inst 85:316-320, 1993
Luikart SD, Goutsou M, Mitchell ED, Van Echo DA,
Modeas CR, Propert KJ, O'Donnell J, Difino S, Perry
MC, Green MR: Phase I/II trial of etoposide and carboplatin
in extensive small cell lung cancer. Am J Clin Oncol
16:127-131, 1993
Graziano SL, Herndon JE II, Richards F II, DiFino
S, Modeas C, Duggan DB, Green MR: Phase I trial of
ifosfamide, mesna and cisplatin in advanced non-small
cell lung cancer: A Cancer and Leukemia Group B study.
Cancer 72:62-68, 1993
Lilenbaum RC, Green MR: Novel chemotherapeutic agents
in the treatment of non-small cell lung cancer. J
Clin Oncol 11:1391-1402, 1993
Green MR: New adjuvant strategies for the management
of resectable non-small-cell lung cancer. Chest 103:352S-355S,
1993
Green MR: New directions for chemotherapy in non-small-cell
lung cancer. Chest 103:370S-372S, 1993
Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki
Y, Modeas C, Herndon JE II, Aisner J, Ellison RR,
Leone L, Vogelzang NJ, Green MR: Randomized phase
II trial of cisplatin with mitomycin or doxorubicin
for malignant mesothelioma by the Cancer and Leukemia
Group B. J Clin Oncol 11:1559-1565, 1993
Kreisman H, Lisbona A, Olson L, Propert KJ, Modeas
C, Dillman RO, Seagren SL, Green MR: Effect of radiologic
stage III substage on nonsurgical therapy of non-small
cell lung cancer. Cancer 72:1588-1596, 1993
Green MR, Kreisman H, Doll DC, Lyss AP, Clamon GH,
Goutsou M, Perry MC, Propert KJ: Carboplatin in non-small
cell lung cancer: An update on the Cancer and Leukemia
B experience. Sem in Oncol 19:(1) Supp 2, 44-49, 1992
Shea TC, Storniolo AM, Mason JR, Newton B, Mullen
M, Taetle R, Green MR: A dose escalation study of
carboplatin, cyclophosphamide and VP-16 along with
autologous bone marrow or peripheral blood stem cell
rescue. Sem in Oncol (supp) (in press, 1993)
Aisner J, Goutsou M, Maurer LH, Cooper R, Chahinian
P, Carey R, Skarin A, Slawson R, Perry MC, Green MR:
Intensive combination chemotherapy, concurrent chest
irradiation, and warfarin for the treatment of limited-disease
small-cell lung cancer: A Cancer and Leukemia Group
B pilot study. J Clin Oncol 10:1230-1236, 1992
Strauss GM, Herndon JE, Sherman DD, Mathisen DJ,
Carey RW, Choi NC, Rege VB, Modeas C, Green MR: Neoadjuvant
chemotherapy and radiotherapy followed by surgery
in stage IIIA non-small-cell carcinoma of the lung:
Report of a Cancer and Leukemia Group B Phase II Study.
J Clin Oncol 10:1237-1244, 1992
Citron ML, Modeas C, Propert K, Goutsou M, Green
MR: Phase II trial of high dose 24-hour continuous
infusion 5-Fluorouracil for advanced non-small cell
lung cancer: A Cancer and Leukemia Group B study.
Cancer Invest 10:215-219, 1992
Lyss AP, Perry MC, Goutsou M, Propert K, Herndon
JE, Mason-Coughlin K, Green MR: Intensive etoposide
and carboplatin chemotherapy for advanced non-small
cell lung cancer: A phase II trial of the Cancer and
Leukemia Group B. Am J Clin Oncol 15:399-404, 1992
Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper
MR, Henderson ES, Green MR, Gottlieb A, Peterson BA:
Chemotherapy of advanced Hodgkin's disease: A prospective
randomized comparison of MOPP, ABVD and MOPP alternating
with ABVD. N Eng J Med 327:1478-1484, 1992
Hargis JB, Anderson JR, Propert KJ, Green MR, Van
Echo DA, Weiss RB: Predicting genitourinary toxicity
in patients receiving cisplatin-based combination
chemotherapy: A Cancer and Leukemia Group B study.
Cancer Chemother Pharmacol 30:291-296, 1992
Vokes EE, Lyss AP, Herndon JE II, Mason-Coughlin
C, Green MR: Intravenous 6-thioguanine or cisplatin,
fluorouracil and leucovorin for advanced non-small
cell lung cancer: A randomized phase II study of the
Cancer and Leukemia Group B. Ann Oncol 3:727-732,
1992
Crawford J, Green MR: The role of colony stimulating
factors as an adjunct to lung cancer chemotherapy.
Lung Cancer 8:153-158, 1992
Green MR: Sequential chemotherapy and radiotherapy
for initial management of stage IIIA and stage IIIB
non-small cell lung cancer -induction chemotherapy.
Lung Cancer 7:77-84, 1991
Vogelzang NJ, Goutsou M, Corson JM, Suzuki Y, Graziano
S, Aisner J, Cooper MR, Coughlin KM, Green MR: Carboplatin
in malignant mesothelioma: A phase II study of the
Cancer and Leukemia Group B. Cancer Chemother Pharmacol
27:239-242, 1991
Dillman RO, Berry C, Ryan KP, Green MR, Seagren SL:
Recent outcomes for patients with carcinoma of the
lung. Cancer Invest 9:9-17, 1991
Richards F II, Perry DJ, Goutsou M, Modeas C, Muchmore
E, Rege V, Chahinian AP, Hirsh V, Poiesz B, Green
MR: Chemotherapy with 5-Fluorouracil (5-FU), cisplatin,
and vinblastine for advanced non-small cell lung cancer:
A randomized phase II study of the Cancer and Leukemia
Group B. Cancer 67:2974-2979, 1991
Ellison RR, Mich R, Cuttner J, Schiffer C, Silver
R, Henderson ES, Green MR, Royston I, Davey FR, Glickman
AS, Holland JF: The effects of post-induction intensification
treatment with cytosine arabinoside and daunorubicine
in acute lymphocytic leukemia of adults: A prospective
randomized clinical trial by Cancer and Leukemia Group
B. J Clin Oncol 9:2002-2015, 1991
Dillman RO, Davis RB, Green MR, Weiss RB, Gottlieb
AJ, Caplan S, Kopel S, Preisler H, McIntyre OR, Schiffer
C: A comparative study of two different doses of cytarabine
for acute myeloid leukemia: A phase III trial of Cancer
and Leukemia Group B. Blood 78:2520-2526, 1991
Hamm JT, Tormey DC, Kohler PC, Haller D, Green M,
Shemano I: Phase I study of Toremifene in patients
with advanced cancer. J Clin Oncol 9:2036-2041 1991
Doll DC, Goutsou M, Graziano S, Ellerton J, Bitran
J, Modeas C, Herndon J, Perry M, Green M: Carboplatin
and vinblastine in advanced non-small-cell lung cancer:
A phase II study. Cancer Chemother Pharmacol 29:71-74,
1991
Green MR: Unresectable stage III non small cell lung
cancer: Lessons and directions from clinical trials
research (Editorial). J Natl Inst Cancer 83:382-383,
1991
Ringenberg QS, Propert KJ, Muss HB, Weiss RB, Schilsky
RL, Modeas C, Perry MC, Norton L, Green MR: Clinical
cardiotoxicity of esorubicin (4'-deoxydoxorubicin,
DxDx): Prospective studies with serial gated heart
scans and reports of selected cases: A Cancer and
Leukemia Group B report. Invest New Drugs 8:221-226,
1990
Graziano SL, Lee K, Propert KJ, Tinsley R, Hayes
DM, Green M, Comis RL: Phase II trial of etoposide
and cisplatin for refractory small cell lung cancer:
A Cancer and Leukemia Group B Study. Med Ped Oncol
18:22-26, 1990
Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton
WL, Perry MC, Carey RW, Frei EF III, Green MR: A randomized
trial of induction chemotherapy plus high-dose radiation
versus radiation alone in stage III non-small cell
lung cancer. New Eng J Med 323:940-945, 1990
Strauss G, Sherman D, Goutsou M, Mathisen D, Carey
R, Choi N, Rege V, Modeas C, Propert K, Green M: Neoadjuvant
chemotherapy and radiotherapy followed by surgery
in stage IIIA non-small cell carcinoma of the lung:
A phase II study of the Cancer and Leukemia Group
B, in Adjuvant Therapy of Cancer VI. Salmon SE, ed.
Philadelphia, W.B. Saunders, 1990, pp 125-132
Kreisman H, Goutsou M, Modeas C, Graziano S, Costanza
M, Green M: Cisplatin-carboplatin therapy in extensive
non-small cell lung cancer: A Cancer and Leukemia
Group B Study. Eur J Cancer 26:1057-1060, 1990
NIH Consensus Development Conference Panel: Adjuvant
therapy for patients with colon and rectal cancer.
JAMA 264:1444-1450, 1990
Green MR, Kramar A, Schilsky R, Stoopler M, Zimmer
B, Richards F II, Skarin A, Anderson JR: Platinum-based
combination chemotherapy in advanced non-small cell
lung cancer: A randomized phase II trial of the Cancer
and Leukemia Group B. Med Ped Oncol 18:197-202, 1990
Parker BA, Vassos AB, Halpern SE, Miller RA, Hupf
H, Amox DG, Sinomi JL, Starr RJ, Green MR, Royston
I: Radioimmunotherapy of human B cell lymphoma 90Y-conjugated
anti-idiotype monoclonal antibody. Cancer Res (suppl.)
50:1022s-1028s, 1990
Green MR, Kreisman H, Luikart S, Lyss A, Bitran JD,
Goutsou M, Propert K: Carboplatin in non-small cell
lung cancer: The Cancer and Leukemia Group B experience,
in Carboplatin (JM-8): Current Perspectives and Future
Directions. Bunn PA, Canetta R, Ozols RF, Rozencweig
M, eds. Philadelphia, W.B. Saunders, 1990, pp. 301-306
Spiegelman D, Maurer LH, Ware JH, Perry MC, Chahinian
AP, Comis R, Eaton W, Zimmer B, Green MR: Prognostic
factors in small cell carcinoma of the lung: An analysis
of 1,521 patients. J Clin Onc 7:344-354, 1989
Green MR: Phase III chemotherapy trials in small
cell lung cancer. Lung Cancer 5:178-185, 1989
Chahinian AP, Propert KJ, Ware JH, Zimmer B, Perry
MC, Hirsh V, Skarin A, Kopel S, Holland JF, Comis
RL, Green MR: A randomized trial of anticoagulation
with warfarin and of alternating chemotherapy in extensive
small cell lung cancer by the Cancer and Leukemia
Group B. J Clin Onc 7:993-1002, 1989
Bunn PA, Cullen M, Fukuoka M, Green M, Hansen HH,
Harper P, Klatersky J, Le Chevalier AT, Sagman U,
Splinter T: Chemotherapy in small cell lung cancer,
in Management of Small Cell Lung Cancer. Amsterdam,
Elsevier, 1989. pp. 9-16
Ringenberg QS, Perry MC, Propert KJ, Modeas C, Hirsh
V, Weiss RB, Richards F II, Graziano S, Green M: Phase
II trial of 4'-deoxy- doxorubicin (DxDx) in non-small
cell lung cancer: A Cancer and Leukemia Group B Trial.
Med Ped Oncol 16:27-29, 1988
Choi NC, Propert K, Carey R, Eaton W, Leone LA, Silberfarb
P, Green MR: Accelerated radiotherapy followed by
chemotherapy for locally recurrent small cell carcinoma
of the lung. A phase II study of the Cancer and Leukemia
Group B. Int J Rad Onc Biol Phys 13:263-266, 1987
Perry MC, Eaton WL, Propert KJ, Ware JH, Zimmer B,
Chahinian AP, Skarin A, Carey RW, Kreisman H, Faulkner
C, Comis R, Green MR: Chemotherapy with or without
radiation therapy in limited small cell carcinoma
of the lung. New Eng J Med 316:912-918, 1987
Luikart SD, Propert KJ, Modeas CR, Green MR, Perry
MC: High-dose etoposide therapy for extensive small
cell lung cancer: A Cancer and Leukemia Group B study.
Cancer Treat Rep 71:533-534, 1987
Kwiatkowski D, Propert K, Carey RW, Choi N, Green
MR: A phase II trial of cyclophosphamide, etoposide
and cisplatin with combined chest and brain radiotherapy
in limited small cell lung cancer: A Cancer and Leukemia
Group B Study. J Clin Oncol 5:1874-1879, 1987
Kreisman H, Ginsberg S, Propert K, Richards F, Graziano
S, Green MR: Carboplatin or iproplatin in advanced
non-small cell lung cancer: A Cancer and Leukemia
Group B Study. Cancer Treat Rep 71: 1049-1052, 1987
Cella DF, Orofiamma B, Holland JC, Silberfarb PM,
Tross S, Feldstein M, Perry MC, Maurer LH, Comis R,
Green MR: Relationship of psychological distress,
extent of disease and performance status in patients
with lung cancer. Cancer 60:1661-1667, 1987
Carey RW, Anderson J, Green MR, Ellison RR, Nathanson
L, Kennedy BJ: Treatment of metastatic malignant melanoma
with Vinblastine, Dacarbazine and Cisplatin (VDD).
Cancer Treat Rep 70:329-331, 1986
Perry MC, Green MR, Mick R, Schein P: Cisplatin in
patients with gastric cancer: A CALGB phase II study.
Cancer Treat Rep 70:415-417, 1986
Green MR, Vosika G, Propert KJ, Ware JH, Comis R:
Bisantrene in non-small cell lung cancer: A phase
II trial of the Cancer and Leukemia Group B. Cancer
Treat Rep 70:539-540, 1986
Shilsky RL, Green MR, Anderson J: Cytarabine Cisplatin
in patients with advanced cancer. Semin Oncol 12:171-176,
1985
Sobol RE, Dillman RO, Collins H, Griffiths JC, Green
MR, Royston I: Applications and limitations of peripheral
blood lymphocyte immunoglobulin light chain analysis
in the evaluation of non-Hodgkin's lymphoma. Cancer
56:2005-2010, 1985
Young JA, Kossman CR, Green MR: Adenocarcinoma of
the fallopian tube: Report of a case with an unusual
pattern of metastasis and response to combination
chemotherapy. Gyn Onc 17:238-240, 1984
Young JA, Howell SB, Green MR: Pharmacokinetics and
toxicity of 5-day continuous infusion of Vinblastine.
Cancer Chemother Pharmacol 12:43-45, 1984
Markman M, Howell SB, Lucas WE, Pfeifle CE, Green
MR: Combination intraperitoneal chemotherapy with
Cisplatin, Cytarabine, and Doxorubicin for refractory
ovarian carcinoma and other malignancies principally
confined to the peritoneal cavity. J Clin Onc, 2:1321-1326,
1984
Markman M, Howell SB, Green MR: Combination intracavitary
chemotherapy for malignant pleural disease. Cancer
Drug Delivery 1:333-36, 1984
Young JA, Green MR, Johnson A, Yon JL, Campbell TN,
Lucas WE, Kroener J, Koziol JA, Saltzstein S: Alternating
combination chemotherapy for stage III and IV ovarian
carcinoma. J Clin Onc 2:1317-1320, 1984
Markman M, Green MR: Disease or treatment-related
complications in patients with non-Hodgkin's lymphomas,
in Your Patient and Cancer, 1984
Amrein PC, Coleman M, Richards F, Poulin RF, Berkowitz
I, Kennedy BJ, Green MR, Herschkopf R, Rafla S: Phase
II study of AMSA in metastatic renal cell carcinoma:
A Cancer and Leukemia Group B study. Cancer Treat
Rep 67:1043-1044, 1983
Dillman RO, Beauregard JC, Lea JW, Green MR, Sobol
RE, Royston I: Chronic lymphocytic leukemia and other
chronic lymphoid proliferations: Surface marker phenotypes
and clinical correlations. J Clin Onc 1:190-197, 1983
Carey RW, Comis RL, Anbar D, Kennedy BJ, Capizzi
RL, Shulman P, Booth BW, Green MR, Raich PC: Cancer
and Leukemia Group B phase II non-small cell lung
carcinoma trial: Aziridinylbenzoquinone (AZQ). Cancer
Treat Rep 67:95-96, 1983
Green MR, Horton MC, Spaulding M, Silver RT, Berenberg
J, Kennedy BJ, Pajak TF, Comis R: Four-drug combination
chemotherapy (Methotrexate, Cyclophosphamide, Hexamethylmelamine,
and CCNU) for non-small cell bronchogenic carcinoma:
A Cancer and Leukemia Group B study. J Clin Onc 1:559-565,
1983
Sobol RE, Dillman RO, Beauregard JC, Yu A, Lea LW,
Collins H, Warmsely S, Green MR, Ellison RR, Royston
I: Clinical utility of monoclonal antibodies in the
phenotyping of acute and chronic lymphocytic leukemia,
in Protides of the Biological Fluids. Peters H, ed.
New York, Perganon Press, 30:417-422, 1983
Green MR: Primary gastrointestinal lymphomas, in
Mediguide to Oncology, Wiernik PH, ed. Lederle, 3:1-5,
1983
Green MR: Epitomes of progress - Internal medicine
chemotherapy for disseminated germ cell cancer. West
J Med 138:708, 1983
Dillman RO, Orth R, Royston I, Greco C, Green MR:
Extracellular paraprotein globules in a patient with
monoclonal gammopathy. Arch Pathol Lab Med 106:275-277,
1982
Young JA, Dillman RO, Seagren SL, Taetle R, Rentschler
RE, Lea JW, Lehar TJ, Green MR, Stanton W, Mendelsohn
J, Royston I: Non-cross-resistant chemotherapy and
consolidation radiotherapy for small cell carcinoma
of the lung. Cancer Treat Rep 66:1399-1401, 1982
Dillman RO, Beauregard JC, Mendelsohn J, Green MR,
Howell SB, Royston I: Phase I trials of thymosin fraction
5 and thymosin dl. J Biol Response Modif 1:35-41,
1982
Howell SB, Pfeifle CL, Wung WE, Olshen RA, Lucas
WE, Yon JL, Green MR: Intraperitoneal cisplatin with
systemic thiosulfate protection. Ann Intern Med 97:845-851,
1982
Amrein PC, Coleman M, Richards R II, Poulin RF, Bernhardt
B, Ginsberg SJ, Green MR, Morrison A, Cortes E, Kiang
D, Weinberg V, Wood WC: Phase II study of AMSA in
patients with metastatic breast cancer: A Cancer and
Leukemia Group B study. Cancer Treat Rep 66:1211-1213,
1982
Yates J, Glidewell O, Wiernik P, Cooper MR, Steinberg
D, Dosik H, Levy R, Hoagland C, Henry P, Gottlieb
A, Cornell C, Berenberg J, Hutchinson LJ, Raich P,
Nissen N, Ellison RR, Frelick R, James GW, Falkson
G, Silver RT, Haurani F, Green MR, Henderson E, Leone
L, Holland JF: Cytosine arabinoside with Daunorubicin
or Adriamycin for therapy of acute myelocytic leukemia:
A Cancer and Leukemia Group B study. Blood 60:454-462,
1982
Green MR, Anderson RE: Acute myelocytic leukemia
following prolonged Streptozotocin therapy. Cancer
47:1963-65, 1981
Mueh JR, Greco CM, Green MR: Spontaneous regression
of metastatic testicular carcinoma in a patient with
bilateral sequential testicular tumor. Cancer 45:2908-2912,
1980
Green MR, Dillman RO, Horton MC: Procarbazine, Vincristine,
CCNU, and Cyclophosphamide (POCC) in the treatment
of metastatic malignant melanoma. Cancer Treat Rep
64:139-142, 1980
Kostinas JE, Leone LA, Cuttner J, Vinciguerra V,
Green MR, DeBellis R, Pajak TF: Procarbazine, Vinblastine,
and Actinomycin D in stage III and IV melanoma with
or without Methanol-extracted residue of bacillus
calmette-Guerin. Cancer Treat Rep 63:197-200, 1979
Green MR: Chemotherapy of head and neck cancer. Head
Neck Surg 1:75-86, 1978
Bachur N, Riggs C, Green MR, Langone J, Van Vunakis
H, Levine L: Human plasma Adriamycin and Daunorubicin
by fluorescence and radioimmunoassay. Clin Pharmacol
Ther 21:70-77, 1977
Green MR: Pulmonary toxicity of antineoplastic agents.
West J Med 127:292-298, 1977
Gutin P, Green MR, Bleyer W, Bauer V, Wiernik P,
Walker M: Methotrexate pneumonitis induced by intrathecal
methotrexate therapy. A case report with pharmacokinetic
data. Cancer 38:1529-1534, 1976
|
